Potential for effective treatment and prevention of periungual fibromas and angiofibromas in tuberous sclerosis
- 15 December 2025
- journal article
- Published by ECO-Vector LLC in Russian Journal of Skin and Venereal Diseases
- Vol. 28 (6) , 643-656
Abstract
Tuberous sclerosis is an orphan neurocutaneous hereditary disorder characterized by multisystem involvement and age-dependent manifestation of symptoms. The disease results from sporadic or inherited mutations in TSC1 (9q34, hamartin) or TSC2 (16p13.3, tuberin). Under normal conditions, TSC1 and TSC2 regulate cell proliferation and tumor growth by inhibiting the mTORC1 complex (mechanistic target of rapamycin complex 1). Mutations in TSC1 and TSC2 disrupt formation of the hamartin–tuberin complex, leading to persistent activation of mTORC1 and uncontrolled cellular proliferation. A detailed description of cutaneous manifestations of tuberous sclerosis is crucial for early diagnosis. Angiofibromas and periungual fibromas are major diagnostic criteria for tuberous sclerosis. Although not life-threatening, these tumors significantly impair patients’ quality of life due to their size, bleeding upon trauma, and risk of secondary infection. Removal of angiofibromas and periungual fibromas substantially improves patients’ quality of life. Various removal techniques have been described in the scientific data, with laser modalities offering practical advantages over surgical excision. We followed two adult patients with large facial angiofibromas and periungual fibromas. Angiofibromas and periungual fibromas were removed using a CO2 laser under local infiltration anesthesia, followed by wound resurfacing with the same device in pulsed mode. Laser output ranged from 2 to 4 W. Immediately after excision, facial angiofibromas were additionally treated intralesionally with a pulsed dye laser. Excised tissue was submitted for histopathologic examination. Outcomes were assessed at 1 month, and patients were subsequently monitored every 3 months for 2 years by a dermatovenereologist. No tumor recurrences were observed during follow-up, underscoring the practical value of this approach for effective fibroma removal and improved quality of life.Keywords
This publication has 26 references indexed in Scilit:
- A dermatological assessment of pediatric patients with tuberous sclerosis complex (TSC)Anais Brasileiros de Dermatologia, 2024
- A Triple Laser Combination Treatment for Facial Angiofibromata Management in Tuberous Sclerosis and Literature ReviewArchives of Plastic Surgery, 2024
- Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management RecommendationsPediatric Neurology, 2021
- Comparison of the functional and structural characteristics of rare TSC2 variants with clinical and genetic findingsHuman Mutation, 2019
- mTOR Signaling in Growth, Metabolism, and DiseaseCell, 2017
- Genotype/Phenotype Correlations in Tuberous Sclerosis ComplexSeminars in Pediatric Neurology, 2015
- Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2European Journal of Human Genetics, 2015
- Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus ConferencePediatric Neurology, 2013
- Rapamycin for treating Tuberous sclerosis and Autism spectrum disordersTrends in Molecular Medicine, 2011
- History of the tuberous sclerosis complexBrain and Development, 1995